Fujifilm pumps $111m into its US biologics and stem cell network

SourceBioProcess International
Date Published01/08/2019
Author NameDan Stanton
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Fujifilm Diosynth Biotechnologies
Parent companyFujifilm Corporation
Type of work Manufacturing
If manufacturing, is the company a contract manufacturer?Yes
Reshoring category:Foreign Direct Investment
Year reshoring announced:2019
Capital investment ($):90
Country(ies) from which reshored:Japan
City reshored to:Morrisville
State(s) reshored to:NC
If relevant, work nearshored to:-
Product(s) reshoredcell cultures and microbial products
What domestic positive factors made reshoring more attractive?Customer responsiveness improvement, Eco-system synergies, Proximity to customers/market
Find Reshoring Articles